Published October 15, 2012
Susa Coffey, MD
Selected Reference
9. Margot NA, Rhee M, Szwarcberg J, et al; GS-US-183-0145 Study Team. Low rates of integrase resistance for elvitegravir and raltegravir through week 96 in the phase 3 clinical study GS-US-183-0145. In: Program and abstracts of the XIX International AIDS Conference; July 22-27, 2012; Washington. Abstract TUPE050.